CYTO
Price
$0.30
Change
-$0.11 (-26.83%)
Updated
Dec 19 closing price
SPHDF
Price
$9.42
Change
-$2.28 (-19.49%)
Updated
Dec 3 closing price
Ad is loading...

CYTO vs SPHDF

Header iconCYTO vs SPHDF Comparison
Open Charts CYTO vs SPHDFBanner chart's image
Altamira Therapeutics
Price$0.30
Change-$0.11 (-26.83%)
Volume$830.27K
CapitalizationN/A
Santhera Pharmaceuticals Holdings
Price$9.42
Change-$2.28 (-19.49%)
Volume$1K
CapitalizationN/A
CYTO vs SPHDF Comparison Chart
Loading...
SPHDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTO vs. SPHDF commentary
Dec 24, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTO is a Hold and SPHDF is a Hold.

COMPARISON
Comparison
Dec 24, 2024
Stock price -- (CYTO: $0.00 vs. SPHDF: $9.42)
Brand notoriety: CYTO and SPHDF are both not notable
Both companies represent the Biotechnology industry
Market capitalization -- CYTO: $1.13M vs. SPHDF: $154.03M
CYTO [@Biotechnology] is valued at $1.13M. SPHDF’s [@Biotechnology] market capitalization is $154.03M. The market cap for tickers in the [@Biotechnology] industry ranges from $363.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTO’s FA Score shows that 1 FA rating(s) are green whileSPHDF’s FA Score has 0 green FA rating(s).

  • CYTO’s FA Score: 1 green, 4 red.
  • SPHDF’s FA Score: 0 green, 5 red.
According to our system of comparison, CYTO is a better buy in the long-term than SPHDF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SPHDF’s TA Score shows that 1 TA indicator(s) are bullish.

  • SPHDF’s TA Score: 1 bullish, 2 bearish.

Price Growth

CYTO (@Biotechnology) experienced а 0.00% price change this week, while SPHDF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.79%. For the same industry, the average monthly price growth was -2.59%, and the average quarterly price growth was +3.59%.

Reported Earning Dates

CYTO is expected to report earnings on Nov 17, 2022.

Industries' Descriptions

@Biotechnology (-1.79% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTOSPHDFCYTO / SPHDF
CapitalizationN/A142M-
EBITDAN/AN/A-
Gain YTDN/A-19.487-
P/E RatioN/A1.46-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
SPHDF: Fundamental Ratings
SPHDF
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
84
P/E GROWTH RATING
1..100
54
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
SPHDF
RSI
ODDS (%)
N/A
Stochastic
ODDS (%)
N/A
Momentum
ODDS (%)
Bullish Trend 4 days ago
40%
MACD
ODDS (%)
N/A
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
11%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
52%
Advances
ODDS (%)
N/A
Declines
ODDS (%)
N/A
BollingerBands
ODDS (%)
N/A
Aroon
ODDS (%)
N/A
View a ticker or compare two or three
Ad is loading...
SPHDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PRGTX21.110.26
+1.25%
T. Rowe Price Global Technology
PHPSX20.710.19
+0.93%
ProFunds Pharmaceuticals UltraSector Svc
MPSIX21.960.13
+0.58%
Principal MidCap S&P 400 Index Inst
ARVIX10.400.03
+0.29%
ARGA International Value Institutional
JSJFX17.03N/A
+0.01%
JHancock Small Cap Dynamic Growth R6

SPHDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPHDF has been closely correlated with TRML. These tickers have moved in lockstep 78% of the time. This A.I.-generated data suggests there is a high statistical probability that if SPHDF jumps, then TRML could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPHDF
1D Price
Change %
SPHDF100%
N/A
TRML - SPHDF
78%
Closely correlated
+1.52%
COGT - SPHDF
63%
Loosely correlated
+0.51%
MEOBF - SPHDF
50%
Loosely correlated
N/A
KROS - SPHDF
38%
Loosely correlated
+0.65%
CYTOF - SPHDF
35%
Loosely correlated
-60.07%
More